Table 2.
Univariate analysis of relapse-free survival for conventional prognostic factors in the test set cohort
| Factor | n/313 | Divisions | n | Median RFS, years (95% CI) | HR (95% CI) | P |
| Overall | 313 | 5.2 (3.9–6.5) | ||||
| Age | 313 | ≤40 | 34 | 2.9 (1.3–4.5) | 1 | |
| >40 | 279 | 5.6 (4.2–7.0) | 0.74 (0.48–1.13) | 0.2 | ||
| Menopausal status | 307 | Pre | 104 | 3.7 (2.1–5.2) | 1 | |
| Post | 203 | 6.0 (3.9–8.2) | 0.79 (0.59–1.05) | 0.1 | ||
| Tumor grade | 297 | 1, 2 | 5, 101 | 9.5 (4.9–14.2) | 1 | |
| 3 | 191 | 4.0 (3.3–4.8) | 1.24 (1.06–1.45) | 0.007 | ||
| Tumor size, cm | 308 | 0 to 2 | 100 | 11.0 | 1 | |
| >2 to 5 | 173 | 4.5 (3.5–5.6) | 1.67 (1.21–2.33) | 0.002 | ||
| >5 | 35 | 3.0 (0–6.2) | 1.55 (0.95–2.54) | 0.08 | ||
| Pathological ER statusa | 306 | Negative | 72 | 2.0 (0.9–3.0) | 1 | |
| Positive | 234 | 6.8 (4.0–9.5) | 0.53 (0.38–0.72) | 0.00007 | ||
| Lymphovascular invasion | 293 | Negative | 49 | 12.0 (5.3–18.8) | 1 | |
| Positive | 244 | 4.5 (3.5–5.4) | 1.73 (1.13–2.66) | 0.01 | ||
| Percentage of positive nodes | 313 | 0–50 | 121 | 9.2 (5.7–12.8) | 1 | |
| >50–99 | 142 | 4.8 (3.5–6.2) | 1.52 (1.11–2.09) | 0.01 | ||
| 100% | 50 | 3.1 (1.8–4.4) | 1.96 (1.30–2.94) | 0.001 | ||
| Number of positive nodes | 313 | 4–9 | 235 | 5.3 (3.9–6.7) | 1 | |
| ≥10 | 78 | 4.8 (2.1–7.6) | 1.16 (0.85–1.60) | 0.4 | ||
| Histology | 313 | Ductal | 279 | 5.1 (3.8–6.5) | 1 | |
| Lobular | 34 | 6.4 (2.7–10.1) | 1.16 (0.76–1.77) | 0.5 |
P, significance for the comparison of hazard ratios; ER, estrogen receptor; RFS, relapse-free survival; CI, confidence interval; HR, hazard ratio.
aPathological ER status at diagnosis.